From 2012 to 2021, 10,397 documents were published on “meningioma”, including 6,714 articles ( Figure 2A ). These articles were published in 1217 journals by 26696 authors, with an average of 6.94 co-authors per article; 87 of these articles were independently authored, and another 17.32% were published in international collaboration. 96,905 references were cited in these articles, with an average of 11.99 citations per article. In addition, these articles have been cited 80,501 times, with an average of 11.99 citations per article.

The annual number of publications in the last decade tended to increase each year, especially from 2016 to 2017 ( Figure 2B ); the annual number of publications increased nearly 1-fold from 483 in 2012 to 935 in 2021, with an average annual growth rate of 8.91%. Each country’s annual publication volume also shows a yearly performance increase. The United States has the highest number of publications (1671), with more than 1000, followed by China with 928, Japan with 496, Germany with 489, and Italy with 339 ( Figure 2C ). Some countries, such as South Korea and France, have concentrated their publications in the early years. In contrast, others have concentrated in recent years, such as Denmark, Egypt, and Saudi Arabia.

A total of 111 countries/regions were involved in meningioma-related research, and their differences in impact were related to the volume of articles published ( Figure 2D ). The overall citation volume of country articles was ranked the same as the volume of publications, with the top five being the United States (27674), China (8427), Germany (8293), Japan (4368), and Italy (4033). However, the number of citations of a single article in different countries shows varying levels. Switzerland has the highest number of citations for a single article, with 22.64, followed by the UK with 17.96 and Germany with 18.86. Although the US and China rank first and second in total citations, they rank 4th and 14th in citations for a single article, with 16.56 and 9.08. The articles published in collaboration between different institutions are mainly domestic but also partially (17.32%) international ( Figures 2E, F ). The most significant inter-country collaborations were in the United States, with China, Germany, and Canada as the leading collaboration countries.

These articles originated from 4835 institutions, with the top 10 publishing more than 100 articles ( Figure 3A ). Three of the top five institutions are from the United States: The University of California (242 articles), Mayo Clinic (208 articles), and Ohio State University (178 articles); the other two institutions are from China: Capital Medical University (205 articles) and Fudan University (172 articles). The top 10 authors are shown in Figure 3B , mainly from China (4), the United States (3), and Germany (2), with the highest number of publications coming from WM (46), followed by DF from the United States and MC from Germany (45). The distribution of the top 20 authors in terms of publication volume is shown in Figure 3C . From the figure, it can be seen that these authors have published at least one article almost every year in the last ten years, with the highest number of articles published in 2019.

The top 10 journals with the most articles related to meningioma are listed in Figure 3D . The most published journal is WORLD NEUROSURGERY (607 articles), accounting for about one-tenth of the total number of articles, followed by the JOURNAL OF NEUROSURGERY (265 articles) and JOURNAL OF NEURO-ONCOLOGY (218 articles). The journals with more than 100 articles also include ACTA NEUROCHIRURGICA (194 articles), CLINICAL NEUROLOGY AND NEUROSURGERY (150 articles), and JOURNAL OF CLINICAL NEUROSCIENCE (142 articles). However, the impact of these journals is not proportional to their number of publications. H-index, g-index, and m-index are the highest for JOURNAL OF NEUROSURGERY with 42, 62, and 3.818, respectively. Followed by NEURO-ONCOLOGY (36, 60, and 3.273)

The top 20 most frequently used keywords in this literature are shown in Figure 4 . As can be seen from the chart, the two most used keywords are related to surgical resection, which are “resection” and “surgical treatment”; the top 5 keywords are also “skull base meningioma”, “mesenchymal meningioma”, and “gamma knife”. Regarding period, the three keywords with the largest span were “resection”, “mesenchymal meningioma”, and “literature”. The keywords at the time of WOS inclusion were displayed according to the utilization size (see Figure 5A ). From the word cloud, it can be seen that the top 5 most recorded keywords are: “tumor”, “surgery”, “management”, “meningioma”, and “cancer”, in that order. VOS viewer was used for co-occurring keywords, and it was found that “classification” became a prominent new keyword around 2018 ( Figure 5B ). A temporal distribution of keywords using citations shows that keywords related to tumor surgery, such as “surgery”, “resection”, and “management”, have been used ( Figure 5C ). In addition, it can be seen that the focus keywords used in the last 3 years, such as “cell”, “microRNA expression”, and “ewelmer”, are related to basic research and molecular characteristics of tumors. It indicates that the research hotspots of meningioma in recent years have gradually favored basic research.

At the same time, we also performed cluster analysis on the keywords. The keywords with more than 50 citations were clustered using VOS viewer ( Figure 5D ). We could see that these keywords were clustered into 5 categories: (i) the red part with “meningioma” as the main keyword was mainly related to the general characteristics and basic research of meningioma; (ii)the green part with “surgery” as the main keyword was mainly related to the surgical resection treatment of meningioma; (iii)the yellow part with “recurrence” and “radiotherapy” as the primary keywords is mainly related to the radiotherapy treatment of meningioma. (iv)the purple part with “stereotactic radiosurgery” as the main keyword is mainly related to stereotactic radiosurgery for meningioma; (v)the blue part with “intracranial meningioma” as the main keyword is mainly related to brain edema and other related complications.

In addition, we listed all keywords with more than 20 citations and performed the artificial statistical analysis. First, considering that “classification” became the most used keyword in 2018, we screened the keywords related to meningioma classification ( Figure 5E ). The figure shows that the main classifications include those based on tumor site and pathological type. Secondly, the keywords related to meningioma management were screened and summarized, and the first 10 keywords in the list are shown in Figure 5F . As we can see from the figure, the primary treatment modalities include surgical resection and radiotherapy or stereotactic radiosurgery. The main content of the study is about survival after treatment and its impact factors. Finally, considering that meningioma molecular characteristics research has gradually become a hot spot in meningioma research in the past 3 years, we screened the related keywords ( Figure 5G ). It can be seen that the hot molecules in basic meningioma research include nf2, akt1, and endothelial growth factor.

From the results of the scientometric analysis of the last 10 years in this paper, it can be seen that: (i) in recent years, meningioma-related research has increased annually and received attention from various countries, with close cooperation among the countries or regions involved in the research; (ii) some scholars and journals have continued to focus on meningioma-related research and achieve specific results and influence, but the influence is not entirely consistent with the total number of articles issued; (iii) in the last decade, the focus of related studies has been gradually refined, with a shift from studies related to meningioma management with surgical resection and radiation therapy as the theme to a shift focusing on tumor differentiation and molecular characteristics studies. In the following, we discuss three aspects of meningioma classification, treatment, and molecular characteristics, combining the results of this study with related literature.

We can see from the scientometric results that in the keyword trend analysis, “classification” was widely cited as a keyword in the period centered on 2018. We believe this may be related to the publication of the fourth edition of the WHO classification of central nervous system tumors in 2016 (3). In this version of the classification, the diagnostic terminology of “integration” with histological and molecular information has been introduced to improve the accuracy of diagnosis and patient treatment, which is an essential guideline for the clinical diagnosis and treatment of meningioma (20, 21). In the recent 2021 update of the WHO Classification of CNS Tumors, the applicability of pathologic histologic features to the staging of meningiomas was continued, while the importance of biological markers for the classification of different grades of meningiomas was emphasized (2). Therefore, in our keyword trend analysis, we can see that meningioma-related molecular characteristics have become a hot research topic in recent years (see “ Meningioma Related Molecular Characteristics” below).

We conducted an artificial screening and statistical analysis of keywords related to meningioma classification. The results showed that these keywords were mainly divided into two categories. One of them is the anatomical classification, including skull base meningioma (22), petroclival meningioma (23, 24), tuberculum sellae meningioma (25), cavernous sinus meningioma (26), olfactory groove meningioma (27) and cerebellopontine keratoma (28), etc. The surgical approach and operative details of meningiomas at different anatomic sites are also different. These clinical studies mainly discuss the most suitable surgical approach and operation for meningiomas in a particular anatomic site to obtain better surgical prognosis for patients (29). The other classification relates mainly to pathological features, including malignant meningioma (30), atypical meningioma (31), anaplastic meningioma (32), and asymptomatic meningioma (33), etc. This classification is primarily associated with treatment modalities and prognosis, such as atypical and anaplastic meningiomas, which tend to have a poor prognosis and require postoperative adjuvant therapy (34, 35).

The latest guidelines suggest that asymptomatic meningiomas without occupying effects can be awaited by annual magnetic resonance imaging (MRI) (4). However, growing or symptomatic meningiomas with occupying effects should be treated by maximum safe resection. Moreover, asymptomatic meningiomas managed by observation usually show rapid growth, requiring a shift in management to surgical resection to reduce the occupancy effect. Most patients have a favorable outcome with maximal resection to reduce the occupancy effect. However, the possibility of recurrence exists for patients with incomplete resection or high-grade meningiomas. And the higher the grade of meningioma, with higher recurrence rates and worse survival rates (36). For instance, compared to benign meningiomas, the 5-year recurrence rate of total tumor excision for atypical meningiomas is 35% to 38%, and the risk of recurrence is 7 to 8 times higher than that of benign meningiomas (33). Therefore, postoperative adjuvant radiotherapy or stereotactic radiosurgery should be considered for this group of patients (34, 37).

As seen in the scientometric results of this study, meningioma management occupies the most significant portion of meningioma research in the last decade (38). Most studies related to meningioma resection include surgery details, the extent of resection, management of postoperative complications, and prognostic factors influencing prognosis. Secondly, radiation therapy and stereotactic radiosurgery are the other two primary management modalities after surgical meningioma resection. Related studies have included adjuvant therapy for specific types of meningiomas (e.g., atypical meningioma and mesenchymal meningioma) and their outcomes (5). In addition, we identified many studies on novel drug treatments for meningiomas in our artificial screening and statistical analysis of keywords. These drug treatments for meningiomas are usually considered experimental and are used as remedial treatments without further local treatment options (39–41). For example, targeted drugs such as anti-angiogenic drugs are used in the remedial treatment of meningiomas (42).

We can see from our analysis of keyword trends that some keywords related to meningioma molecular characteristics are gradually increasing, such as NF2 and AKT1. The trends may be related to the significant progress in research on meningioma molecular characteristics in recent years. Studies have shown that NF2 variants, including shift mutations, allelic inactivation, and missense mutations, could be detected in approximately 60% of meningiomas (2, 43). In addition to NF2, mutations were found in TRAF7, SMO, KLF4, PI3K and AKT1 (44). Non-NF2 variants of meningiomas are more complex and include Hedgehog signaling pathway variants (SMO, SUFU, PRKAR1A, PTCH1/2, etc.), phosphatidylinositol 3-kinase (PI3K) signaling pathway variants (PTEN, AKT1, PIK3CA, PIK3R1, etc.), chromosome remodeling complex variants (SMARCB1, SMARCE1, ARID1A, PBRM1, etc.) and other gene variants (KLF4, BAP1, POLR2A, DMD, etc.) (43).

Some molecular characteristics are associated with histological subtypes of meningioma. For example, TRAF7 and KLF4 mutations are molecular biological markers of secretory meningioma (43), RAF7, POLR2A, and ATK1 mutations are markers of endothelial meningioma (43, 45), SMARCE1 mutations are markers of clear cell meningioma (46), and BAP1 and PBRM1 mutations are markers of rhabdoid and papillary meningioma (47–49). Another part is related to the degree of tumor malignancy, such as the deletion of histone H3 K27me3 expression is closely associated with meningioma recurrence (50–52), TERT promoter mutation and CDKN2A/B pure deletion are molecular biological markers of CNS WHO grade 3 meningioma (53, 54). In addition, changes in DNA methylation levels or expression of specific genes (e.g., NRDG2, MEG3, PDGFR, etc.) are also closely associated with the development of meningiomas (46, 55). Based on DNA methylation characteristics, meningiomas can be subtyped, with differences in anatomic sites, driver genes, and clinical prognosis among subtypes (56). The study of meningioma molecular characteristics is beneficial for further typing of meningiomas and diagnosing and treating tumors. It has been gradually becoming a hot issue in meningioma research.